Dr. Gitlitz on EGFR Exon 20 Insertion Mutations in Lung Cancer

Barbara J. Gitlitz, MD
Published: Friday, Aug 28, 2015

Barbara J. Gitlitz, MD, associate professor of Clinical Medicine, Keck Hospital of USC Norris Comprehensive Cancer Center, discusses treating patients with EGFR exon 20 insertion mutations in lung cancer.

 Exon 20 insertion mutations are the third most common type of EGFR mutation that patients with lung cancer present with, says Gitlitz. While this mutation will show up in a report as an EGFR mutation, it does not respond to any currently available EGFR inhibitors. It is important to be aware that a patient with an EGFR mutation has an exon 20 insertion, explains Gitlitz.

 Exon 20 insertion mutations are currently a target without a treatment, says Gitlitz. More clinical trials are needed.

SELECTED
LANGUAGE

Barbara J. Gitlitz, MD, associate professor of Clinical Medicine, Keck Hospital of USC Norris Comprehensive Cancer Center, discusses treating patients with EGFR exon 20 insertion mutations in lung cancer.

 Exon 20 insertion mutations are the third most common type of EGFR mutation that patients with lung cancer present with, says Gitlitz. While this mutation will show up in a report as an EGFR mutation, it does not respond to any currently available EGFR inhibitors. It is important to be aware that a patient with an EGFR mutation has an exon 20 insertion, explains Gitlitz.

 Exon 20 insertion mutations are currently a target without a treatment, says Gitlitz. More clinical trials are needed.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Year in Review™: Reflecting on Recent Evidence With an Eye to the Future of Lung Cancer ManagementMar 30, 20191.5
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x